2,6-dinitrotoluene appears as yellow to red solid or heated liquid with a slight odor. Solidifies in cool water. Solid and liquid sink in water. (USCG, 1999)
Hydrolyzed urine from workers exposed to dinitrotoluene contained 2,4- and 2,6-DNT, 2,4- and 2,6-dinitrobenzoic acid, 2,4- and 2,6-dinitrobenzyl alcohol, 2-amino-4-nitrobenzoic acid, and 2-(N-acetyl)amino-4-nitrobenzoic acid. ... The percentages of 2,4- and 2,6-DNT metabolites in the urine of individual subjects ranged from 79% to 93%.
Bioactivation of dinitrotoluene in the rat is thought to occur by the following processes: The methyl group is oxidized to an alcohol by a cytochrome p450 dependent pathway; the benzyl alcohol is conjugated with glucoronic acid and excreted in the bile. Intestinal microflora hydrolyze the glucuronide and reduce one nitro group, forming an aminonitrobenzyl alcohol which can be readsorbed from the intestine. The amino group oxidized to an hydroxylamine by hepatic enzymes and conjugated with sulfate. Decomposition of the sulfate ester yields a highly electrophilic nitrenium (or carbonium) ion which can react with DNA and other biological nucleophiles.
Urine specimens were collected over 72 hr from workers at a dinitrotoluene manufacturing plant. Samples were analyzed for 2,4- and 2,6-DNT and putative metabolites by GC/MS. Urine from workers exposed to dinitrotoluene contained 2,4- and 2,6-DNT, 2,4- and 2,6-dinitrobenzoic acid, 2,4-and 2,6-dinitrobenzyl glucuronide, 2-amino-4-nitrobenzoic acid and N-(acetyl)amino-4-nitrobenzoic acid. Excretion of these metabolites peaked near the end of the workshift, but declined to low or undetectable concentrations by the start of work the following day. The calculated half-times for elimination of total dinitrotoluene-related material detected in urine ranged from 1.0-2.7 hr, and those of individual metabolites from 0.8-4.5 hr. The most abundant metabolites were 2,4-dinitrobenzoic acid and 2-amino-4-nitrobenzoic acid, collectively accounting for 74-86% of the dinitrotoluene metabolites detected.
来源:Hazardous Substances Data Bank (HSDB)
代谢
研究了Fischer 344大鼠体内和离体灌流肝脏中肝致癌物2,6-二硝基甲苯(2,6-DNT)的代谢和排泄。给药(10 mg/kg)后72小时内,尿液排泄占剂量的半数。(14)C-2,6-DNT的尿液排泄中,2,6-二硝基苯甲酸、2,6-二硝基苄醇葡萄糖苷酸和2-氨基-6-硝基苯甲酸占了95%。72小时内,粪便排泄占剂量的五分之一。在离体灌流大鼠肝脏的灌洗液和胆汁中,2,6-二硝基苄醇葡萄糖苷酸是主要的代谢物。雄性大鼠肝脏对2,6-二硝基苄醇葡萄糖苷酸的胆汁排泄量是雌性大鼠的3.3倍和8.6倍,分别对应20和70 uM (14)C 2,6-DNT的灌流。胆汁流量没有观察到性别依赖性差异。在雄性大鼠肝脏中,与肝大分子共价结合的(14)C是雌性大鼠的两倍。2,6-二硝基苄醇葡萄糖苷酸胆汁排泄量减少可能解释了雌性大鼠肝脏中共价结合的(14)C较少。2,6-DNT的观察结果与2,4-DNT的观察结果相似,表明这两种异构体都由肝脏代谢,在胆汁中排泄,被肠道微生物群脱结合并进一步代谢,然后可能被运输回肝脏进行额外的代谢,并与肝脏的内源性成分共价结合。
The metabolism and excretion of the hepatocarcinogen 2,6-DNT was investigated in Fischer 344 rats in vivo and in isolated perfused livers. Urinary excretion accounted for half of the dose (10 mg/kg) 72 hr after administration of (14)C-2,6-DNT. 2,6-Dinitrobenzoic acid, 2,6-dinitrobenzyl alcohol glucuronide, and 2-amino-6-nitrobenzoic acid accounted for 95% of the urinary (14)C. Fecal excretion accounted for 1/5 of the dose in 72 hr. 2,6-Dinitrobenzyl alcohol glucoronide was the major metabolite found in the perfusate and bile of isolated perfused rat livers. Biliary excretion of 2,6-dinitrobenzyl alcohol glucoronide by livers from male rats was 3.3 and 8.6-fold that of female rats on perfusion with 20 and 70 uM (14)C 2,6-DNT, respectively. No sex-dependent differences in biliary flow rates were observed. Twice as much (14)C was found to be covalently bound to hepatic macromolecules in male than female rat livers in vivo. Decreased biliary excretion of 2,6-dinitrobenzyl alcohol glucoronide may account for the lesser amount of (14)C found to be covalently bound in female rat livers. Observations with 2,6-DNT parallel those made with 2,4-DNT, suggesting that both isomers are metabolized by the liver, excreted in the bile, deconjugated and further metabolized by the intestinal microflora, and transported back to the liver for, perhaps, additional metabolism and covalent binding to an endogenous component of the liver.
The metabolism of 2,6-DNT occurs in the liver and also in the intestine by microflora. Both oxidized and reduced metabolites are excreted in the urine after oral administration of the compound. Oxidative metabolism by cytochrome P450 predominates in the liver, leading to the formation of dinitrobenzyl alcohol which is either converted to glucuronide conjugate or further oxidized to dinitrobenzoic acid. Dinitrobenzyl alcohol glucuronide is partially excreted into the bile, followed by metabolism by gut microflora and enterohepatic cycling (nitroreductase). Thus, 2,6-DNT appears to be first metabolized by the liver with the metabolites being excreted into the bile; the biliary metabolites are hydrolyzed and further metabolized in the intestine; after reabsorption and circulation back to the liver, a portion of the metabolites (2-amino-6-nitrobenzyl) are oxidized to a hydroxylamine by hepatic enzymes. The hydroxylamine is then conjugated with sulfate by hepatic sulfotransferase. The unstable N-sulfate decomposes to form an electrophilic nitrenium ion, which can react with cellular nucleophiles such as DNA. 2,6-Dinitrobenzyl alcohol glucuronide, 2-amino-6-nitrotoluene, and 2,6-dinitrobenzaldehyde can be detected in the bile. Some amounts of 2,6-dinitrobenzylalcohol and 2-amino-6nitrobenzyl alcohol can also be found. (L276)
Dinitrotoluene may cause conversion of oxyhemoglobin to methemoglobin via oxidation of iron(II) to iron(III) by its metabolites. High levels of methemoglobin are removed by catabolism, leading to the development of anemia. Some metabolites of dinitrotoluene are also transported back from the bile to the liver, where the amine group is N-hydroxylated by cytochrome P-450 to form an unstable sulfate conjugate. The sulfate conjugate is degraded into carbonium or nitrenium ions. These ions covalently bind to hepatic macromolecules (DNA, RNA), leading to mutations and subsequently liver tumors. They also bind to DNA of the lung and the intestine. (L276)
Evaluation: There is inadequate evidence in humans for the carcinogenicity of ... 2,6-dinitrotoluene. There is sufficient evidence in experimental animals for the carcinogenicity of ... 2,6-dinitrotoluene. Overall evaluation: ... 2,6-Dinitrotoluene /is/ possibly carcinogenic to humans (Group 2B).
来源:Hazardous Substances Data Bank (HSDB)
毒理性
致癌性证据
A3:已确认对动物有致癌性,但对人类的相关性未知。/二硝基甲苯/
A3: Confirmed animal carcinogen with unknown relevance to humans. /Dinitrotoluene/
来源:Hazardous Substances Data Bank (HSDB)
毒理性
致癌物分类
国际癌症研究机构致癌物:2,6-二硝基甲苯
IARC Carcinogenic Agent:2,6-Dinitrotoluene
来源:International Agency for Research on Cancer (IARC)
毒理性
致癌物分类
国际癌症研究机构(IARC)致癌物分类:2B组:可能对人类致癌
IARC Carcinogenic Classes:Group 2B: Possibly carcinogenic to humans
来源:International Agency for Research on Cancer (IARC)
After ip and oral administration of 2,6-DNT, the distribution and elimination were determined in strain A mice. In a 30 wk bioassay and at total ip doses of 600, 1500, or 3000 mg/kg, or total oral doses of 1200, 3000, or 6000 mg/kg, the urine was the major route of elimination of both ip and orally administered (3)H-labeled 2,6-DNT, with 87.6, 55.2 and 49.1% of ip doses of 1, 10 and 100 mg/kg, respectively, excreted within 4 hr. The corresponding amounts excreted after oral administration were 33.6, 25.2 and 24.3%, which increased to 53.7, 53.5 and 48.6% after 8 hr. The distribution of 2,6-DNT in various tissues (blood, liver, kidneys, lungs, small and large intestine) showed no evidence for preferential uptake or retention at any of the ip or po doses. Terminal half-lives of radioactive material in the liver were 1.11, 0.95 and 1.16 hr after ip doses of 1, 10 and 100 mg/kg, respectively.
[EN] INHIBITORS OF KRAS G12C<br/>[FR] INHIBITEURS DE K-RAS G12C
申请人:ARAXES PHARMA LLC
公开号:WO2015054572A1
公开(公告)日:2015-04-16
Compounds having activity as inhibitors of G12C mutant KRAS protein are provided. The compounds have the following structure (I): or a pharmaceutically acceptable salt, tautomer, prodrug or stereoisomer thereof, wherein R1, R2a, R3a, R3b, R4a, R4b, G1, G2, L1, L2, m1, m2, A, B, W, X, Y, Z and E are as defined herein. Methods associated with preparation and use of such compounds, pharmaceutical compositions comprising such compounds and methods to modulate the activity of G12C mutant KRAS protein for treatment of disorders, such as cancer, are also provided.
Selective Partial Hydrogenation of Dinitrobenzenes to Nitroanilines Catalyzed by Ru/C
作者:Jie Hou、Yonghuan Ma、Yuhan Li、Fang Guo、Lianhai Lu
DOI:10.1246/cl.2008.974
日期:2008.9.5
Ru/C was found to be a highly effective catalyst for the selective partial hydrogenation of a range of dinitrobenzenes to their corresponding nitroanilines with excellent selectivity under mild conditions. Furthermore, the effect from other substitute groups of dinitrobenzenes on partial hydrogenation was also explored in this study.
Regioselective dinitration of simple aromatics over zeolite Hβ/nitric acid/acid anhydride systems
作者:Keith Smith、Mohammad Hayal Alotaibi、Gamal A. El-Hiti
DOI:10.3998/ark.5550190.p008.527
日期:——
Various nitrationsystemscomprisingnitricacid, acidanhydride and zeolite Hβ in the absence of solvent are described. Direct double nitration of toluene with a nitricacid, propanoic anhydride and zeolite H system has been developed to give 2,4-dinitrotoluene in 98% yield, with a 2,4:2,6-dinitrotoluene ratio of 123:1. This system also nitrates activated mono-substituted benzenes (anisole and phenetole)
o-Xylene, phenol and toluene were nitrated with 100% nitricacid on MoO3/SiO2, WO3/SiO2, TiO2/SiO2, and TiO2–WO3/SiO2 systems. Phenol and toluene were nitrated with yields higher than 90%, and the 10% and 15% MoO3/SiO2 catalysts were most active in the nitration of o-xylene. The most active catalysts exhibited the para-position selectivity of nitration.
safe and expedient conduct of high energetic reactions and potentiallyhazardous chemistry. Apart from handling benefits (such as minimised problems inthe scale-up process), reactions in microreactors proceed under precisely controlled conditions providing improved yields and product quality compared to the batch procedure. In this paper, the potential of this technology is exemplarily determined in
微反应器中的连续处理代表了一种安全和方便地进行高能反应和潜在危险化学的新方法。除了处理优势(例如放大过程中的问题最小化)外,微反应器中的反应在精确控制的条件下进行,与分批程序相比,提供了更高的产率和产品质量。在本文中,该技术的潜力示例性地确定在药物相关中间体 1-甲基-3-丙基-1H-吡唑-5-羧酸 (1) 的关键硝化中。进一步的基本硝化示例证明了危险的 H 2 SO 4 / HNO 3 混合物在 2-甲基吲哚 (4) 和吡啶-N-氧化物 (6) 甚至爆炸性乙酰硝酸酯 Ac 2 O/HNO 3 的硝化中的处理没有问题(甲苯硝化,